Near-death experiences occur when the soul leaves the nervous system and enters the universe, claim two quantum physics experts

Daily Mail, Damien Gayle, 30 October 2012

• Ground-breaking theory holds that quantum substances form the soul
• They are part of the fundamental structure of the universe

Life after death: Dr Stuart Hameroff,
Professor Emeritus at the University of
Arizona, advancedthe theory on a 
television documentary

A near-death experience happens when quantum substances which form the soul leave the nervous system and enter the universe at large, according to a remarkable theory proposed by two eminent scientists.

According to this idea, consciousness is a program for a quantum computer in the brain which can persist in the universe even after death, explaining the perceptions of those who have near-death experiences.

Dr Stuart Hameroff, Professor Emeritus at the Departments of Anesthesiology and Psychology and the Director of the Centre of Consciousness Studies at the University of Arizona, has advanced the quasi-religious theory.

It is based on a quantum theory of consciousness he and British physicist Sir Roger Penrose have developed which holds that the essence of our soul is contained inside structures called microtubules within brain cells.

They have argued that our experience of consciousness is the result of quantum gravity effects in these microtubules, a theory which they dubbed orchestrated objective reduction (Orch-OR).

Thus it is held that our souls are more than the interaction of neurons in the brain. They are in fact constructed from the very fabric of the universe - and may have existed since the beginning of time.

More...

• Evolution of sight traced back 700m years to jellyfish which first developed the abilityto detect light
• The next silicon? IBM reveal groundbreaking technique to mass produce 'carbon chips'that could could dramatically improve everything from supercomputers to mobile phones
• Sea bed wired up with thousands of kilometres of living electrical cables made of bacteria, says new study

The concept is similar to the Buddhist and Hindu belief that consciousness is an integral part of the universe - and indeed that it is really all there may be, a position similar to Western philosophical idealism.

With these beliefs, Dr Hameroff holds that in a near-death experience the microtubules lose their quantum state, but the information within them is not destroyed. Instead it merely leaves the body and returns to the cosmos.

Shocked back to life: The theory holds that when patients have a near death
experience  their quantum soul is released from the body and re-enters the
cosmos, before returning when they are revived

Dr Hameroff told the Science Channel's Through the Wormhole documentary: 'Let's say the heart stops beating, the blood stops flowing, the microtubules lose their quantum state.

'The quantum information within the microtubules is not destroyed, it can't be destroyed, it just distributes and dissipates to the universe at large.

'If the patient is resuscitated, revived, this quantum information can go back into the microtubules and the patient says "I had a near death experience".'

He adds: 'If they're not revived, and the patient dies, it's possible that this quantum information can exist outside the body, perhaps indefinitely, as a soul.'

Evidence: Dr Hameroff believes new findings about the role quantum physics
 plays in biological processes, such as the navigation of birds, will one day
prove his theory

The Orch-OR theory has come in for heavy criticism by more empirically minded thinkers and remains controversial among the scientific community.

MIT physicist Max Tegmark is just one of the many scientists to have challenged it, in a 2000 paper that is widely cited by opponents, the Huffington Post reports.

Nevertheless, Dr Hameroff believes that research in to quantum physics is beginning to validate Orch-Or, with quantum effects recently being shown to support many important biological processes, such as smell, bird navigation and photosynthesis.

Related Articles:

The Afterlife Investigations - Movie Feature - The Scole Experiments

Evidence of Afterlife, Says Radiation Oncologist

Big Bang: Is there room for God?

"The Big Picture - You Are Not Alone" - (a message from Kryon channeled by Lee Carroll

"Perceptions of God" – June 6, 2010 (Kryon channeled by Lee Carroll) (Subjects: Quantum Teaching, The Fear of God, Near-death Experience, God Becomes Mythology, Worship, Mastery, Intelligent Design, Benevolent Creator,Global Unity.... etc.) (Text version)

“… When a Human almost dies, they get close to the veil, very close. They are ever so close to the creator's energy and just barely touched by it. When their heart was stopping and their breathing was almost gone, before they were brought back to life with science, they got to touch the hand of God for just an instant. What they saw was magnificent! The energy before them was filled with love and light, filled with family, filled with beauty. There was no strife there. There was no punishment there or even the hint of it. And when they came back from that experience, listen to what they told you. It changed their lives, didn't it? Listen to each one talk about it, for they continued to say, "There is nothing to fear and death is something you experience as a normal transition." Blessed is the Human Being who experiences both death and birth and has the wisdom to report, "Oh, it's uncomfortable, but I'll get through it, because I've done it before." The person who has experienced a near-death experience is no longer afraid to die! What does that tell you? They have seen what is there and they embrace it! …”

"The Quantum Factor" – Apr 10, 2011 (Kryon channeled by Lee Carroll) (Subjects: Galaxies, Universe, Intelligent design, Benevolent design, Aliens, Nikola Tesla (Quantum energy), Inter-Planetary Travel, DNA, Genes, Stem Cells, Cells, Rejuvenation, Shift of Human Consciousness, Spontaneous Remission, Religion, Dictators, Africa, China, Nuclear Power, Sustainable Development, Animals, Global Unity.. etc.) - (Text Version)

"..... DNA - A Quantum Force 

Now we get to the core truth, don't we? So I will tell you. The ninety percent of DNA which is quantum, is filled with information, both esoteric and timeless. It is a quantum blueprint for everything you are and have been since you arrived on the planet the first time. DNA contains instruction sets for your life; everything from your full Akashic Record - every single lifetime you have had - to the benevolent creator's fingerprint within the seeds of creation itself. Every single talent you ever had is there, even if you don't have any of those today... the record is there. Every predisposition of weakness and strength are there. Biologically, every single instruction to every single stem cell is there. . ..."

"..... DNA is a Dynamic Molecule, not a static one.

Humanity is stuck in the 3D portion of their biological thinking. In your 3-D life, you simply accept the chemistry you're given. You act as though the three percent gene producing part is all there is. You believe it is a chemical protocol that is unchangeable and simply "you." You don't see it for the way it's designed. It's dynamic and always has been. It's not set, but will continue to simply repeat what it does unless there is another quantum influence on it.

Therefore you live with the 3 percent as though it were all there is, and since it just "came with your body" and seems to control everything, you never talk to it. Many of you come in with pre-dispositions based upon the karma which is put upon you from your past lives. You don't come in clean [without karmic energy]. Instead, you arrive with pre-dispositions, fears and phobias. Some are positive. Perhaps you come in as a prodigy continuing your last life... the 8-year-old who can paint like a master and do brushstrokes that take 30 years to develop. What does that tell you about what must be in the DNA?

Perhaps you come in as the composer, the pianist, the prodigy, the violinist, just waiting until your hands can go on the fingerboard or can reach up and fret the notes. Perhaps you come in knowing how to play the piano, just waiting for your hands to get big enough to do what you used to do... without any lessons. How do you explain that, dear ones? The answer is that all this is contained in the dynamic quantum instruction sets of your DNA... the part you never talk to it. .."

Alma Deutscher, 7-Year-Old Prodigious Composer, May Be This Generation's Mozart

Cancer fight stalls amid push for profits, doctors say

Newer drugs fall short of hopes and cost too much, say experts who pledge to improve care in poorer countries

The Guardian, Sarah Boseley, health editor,  Sunday 28 October 2012

Drugs such as tamoxifen, discovered decades ago, provided genuine
breakthroughs  in cancer care unlike the latest generation of medicines,
experts said. Photograph: Paul Beard Photo Agency/Alamy

Progress against cancer is stalling, with the latest targeted cancer drugs failing to live up to expectations and priced so high that treatment is becoming unaffordable even in rich countries, according to experts at a meeting of nearly 100 eminent cancer specialists from around the world.

At the two-day meeting in Lugano, Switzerland, the doctors agreed a 10-point declaration, to be published early next year, which will chart the way forward for cancer care around the globe. Much needs to be done, they believe, to improve treatment, care and prevention both in the developed world and in poor countries, where cancer rates are rising even faster. They agreed to embark on an ambitious plan to get essential cancer care to those who are dying early in developing countries, in the same way that Aids doctors took on the fight to get HIV treatment into hard-hit Africa.

The meeting of the World Oncology Forum, organised by the European School of Oncology and attended by experts such as epidemiologists Sir Richard Peto and Prof Michel Coleman as well as the government's national cancer director, Sir Mike Richards, agreed urgent action was needed on many fronts.

Only a few years ago, many cancer experts thought the arrival of targeted medicines, designed to attack the genetic makeup of the tumour, would make dramatic inroads into cancer deaths. That has not happened. Instead, these therapies have only bought a few extra months of life. If the question was whether the world was winning the war on cancer, said Douglas Hanahan of the Swiss Institute for Experimental Cancer Research, who outlined the latest state of drug research, "in general, for most forms of human cancer, the answer is clearly no".

The excitement generated by targeted drugs, which interfere with specific molecules involved in tumour growth and suppression, has been short-lived.

Doctors reported apparently miraculous results from the use of the BRAF-inhibitor vemurafenib in advanced malignant melanoma, a usually fatal form of skin cancer. Within two weeks, the tumours had melted away.

"But six months later, [the cancer] is back with a vengeance," he said.

Other drugs working in a similar way – including erlotinib (Tarceva) for a form of lung cancer, bevacizumab (Avastin) for breast, colorectal and other cancers, and sunitinib (Sutent) for renal cell carcinoma and gastrointestinal sarcoma – have also not done so well, said Hanahan. Resistance to the drugs builds up, sometimes very quickly. "All came on line with great expectations. The reality check is they are all working in the important first step, but we have a long way to go in terms of winning the war."

The future is probably using these drugs together or in combination with other, older types of drugs, but the price is likely to be prohibitive.

A year's treatment with vemurafenib alone would cost £91,000. Even though the manufacturer, Roche, has offered an undisclosed discount to the Department of Health, the National Institute for Health and Clinical Excellence said in June it was too much for the NHS to pay. No health service will be able to afford to put a patient on two or three such drugs at the same time.

Doctors at the meeting said pharmaceutical industry prices were unsustainable – and the pursuit of profits stopped companies taking part in trials of combinations of their drugs with those of their competitors, which might help patients. They were also said to be not interested in testing their drugs combined with older drugs that are out of patent.

Prof Alexander Eggermont, general director of the Gustave Roussy Cancer Institute in France, said the "economic models of molecular medicine are very uncertain, because if you don't produce cures, you don't know if it is going to sell".

Decades ago, genuine breakthrough drugs were discovered which continue to have a huge impact on the disease. Peto, an epidemiologist at Oxford University, pointed out that five years of tamoxifen reduces mortality in most breast cancers by a third and the benefits continue even after a woman stops taking it. It now appears that taking it for 10 years is even more effective. Nobody knows why resistance does not develop, as it does with the new drugs.

But the meeting agreed that while changes are needed in research, regulation and funding to speed progress on new drugs for intractable cancers, a great deal could and must be done now to tackle cancer in less well-off countries where children and women, in particular, are dying of preventable and curable diseases.

"The divide is such that in Canada almost 90% [of children with leukaemia] can hope to survive while in the poorest countries of the world, 90% are expected to die," said Prof Felicia Knaul, director of the Harvard University global equity initiative.

Between a third and a half of all cancers – 2.4m to 3.7m a year – are preventable, said Knaul, and 80% of those are in lower- and middle-income countries. Preventing and treating them would offer potential productivity savings globally of more than $130bn (£80bn) a year – far more than the cost of treatment.

Cheap vaccines and basic screening can prevent and detect cervical cancer, which kills young women and mothers; cheap hepatitis B vaccination protects against liver cancer; and screening picks up breast cancer early. The dire shortage of morphine and other opioid drugs in developing countries to relieve suffering from cancer pain must be addressed, the doctors said.

Rifat Atun, professor of international health management at Imperial College Business School, called on doctors and scientists to have "bold ambition" and follow the lead of clinicians involved in the Aids response.

"Prevention is important and we need to do it. That does not mean we should not be providing treatment," he said. A decade ago, people said it was not possible to get antiretroviral drugs to patients with HIV in Africa. There are now more than 8 million people in lower-income countries on them.

The forum agreed to a 10-point plan including a goal to cut deaths globally, oppose tobacco – possibly by a tax on manufacturers' profits – accelerate research and get an essential package of cancer care to poor countries.

Related Articles:

The drugs don't work: a modern medical scandal

50 percent of France’s drugs ‘useless’ – top French doctors


AIDS Was a Man-Made Pandemic


"THE BRIDGE OF SWORDS" – Sep 29, 2012 (Kryon channeled by Lee Carroll) - Text Version)

"..  I'm in Canada and I know it, but I will tell those listening and reading in the American audience the following: Get ready! Because there are some institutions that are yet to fall, ones that don't have integrity and that could never be helped with a bail out. Again, we tell you the biggest one is big pharma, and we told you that before. It's inevitable. If not now, then in a decade. It's inevitable and they will fight to stay alive and they will not be crossing the bridge. For on the other side of the bridge is a new way, not just for medicine but for care. ...."

Test allows doctors to see disease without microscope

Google – AFP, 28 October 2012

A scientist holds blood samples in a laboratory (AFP/File, Luis Robayo)

PARIS — Scientists in Britain say they have developed a super-sensitive test using nano-particles to spot markers for cancer or the AIDS virus in human blood serum using the naked eye.

As it does not need sophisticated equipment, the test-tube technique should be cheap and simple, making it a a boon for disease detection in poor countries, the team wrote in Nature Nanotechnology on Sunday.

Researchers from Imperial College London used the technology to scan for molecules of p24, a marker for HIV infection, and Prostate Specific Antigen or PSA, an early indicator of prostate cancer.

Their method is used to analyse serum, a light-yellow fluid that is extracted from blood by a centifuge and is commonly used in health tests.

"If the result is positive for p24 or PSA, there is a reaction that generates irregular clumps of nanoparticles, which give off a distinctive blue hue in a solution inside the container," said a statement.

The reaction, in response to the presence of antibodies, occurred even at ultra-low concentrations of p24 or PSA.

"If the results are negative, the nanoparticles separate into ball-like shapes, creating a reddish hue. Both reactions can be easily seen by the naked eye."

Nanoparticles are microscopic clusters of atoms sized between one and 100 nanometres (a billionth of a metre), that are seen as a promising field of research for their potential in delivering medicines, for example.

The team said their visual sensor technology was 10 times more sensitive than existing standard methods for measuring p24 and PSA biomarkers -- molecules that can indicate the presence of disease.

It was able to detect minute levels of p24 in patients with low viral loads that went undetected using some existing tests.

The new method was also 10 times cheaper.

Study co-author Roberto de la Rica said the test would allow people to be diagnosed at an earlier state of disease, and thus treated sooner.

"We also believe that this test could be significantly cheaper to administer, which could pave the way for more widespread use of HIV testing in poorer parts of the world."

But study co-author Molly Stevens told AFP the method had yet to be tested in a large patient trial to confirm its usefulness.

As yet, the technique cannot pinpoint how big the concentration of HIV or cancer markers is.

"It is an 'on-off' test," Stevens cautioned. "It does not say specifically how many biomarkers are in blood, but only if they are present."

Related Articles:

Cheap colour test picks up HIV

Gene 'barcode' scans men for prostate cancer

KLM stars in new documentary about AIDS

RNW, Tom Onsman, 18 October 2012

(Photo: VARA)

               

Dutch doctors diagnosed the first case of HIV in 1982. The 30th anniversary of the arrival of AIDS in the Netherlands is no reason for celebration, but Dutch public broadcaster VARA is marking the event by broadcasting a documentary this evening, entitled: “Grounded by AIDS”.

The main character in the documentary is the Dutch national airline KLM, a company that was hit hard by the new disease in the 1980s. Documentary-maker Hetty Nietsch came up with the idea several years ago after speaking to Dr.  Joep Lange, a renowned Dutch professor of infectious diseases. The first group of AIDS patients he and his fellow physicians saw at the Academic Medical Centre (AMC) in Amsterdam were all gay men. Many of them worked for airlines, particularly KLM. The flight attendants travelled all over the world. They had sexual encounters in numerous cities and brought the virus back to the Netherlands.

"Mysterious gay cancer”

Nietsche managed to discover the names of 35 of the victims. It’s unclear how many KLM employees died of AIDS. The company doesn’t register the cause of death, and many stewards who became ill didn’t want others to know their status. “If you had cancer”, says former purser Dennis van Puimbrouck, “then you were a victim. If you had AIDS, you were a pervert.” 30 of the colleagues he trained with died of what was then considered a mysterious gay cancer. “The impact was enormous”, says van Puimbrouck. “It was a huge blow to gay emancipation at a time when homosexuals were only beginning to come out of the closet.

In the documentary, Nietsch presents a colourful picture of the atmosphere 30 years ago. It was a time when KLM was booming: its jumbo jets were flying to the furthest corners of the globe, including Sydney, New York, Rio de Janeiro and San Francisco, all popular destinations for the company’s gay stewards. At the time, Amsterdam’s gay scene paled in comparison.

The world’s first AIDS patient was also a steward. He didn’t work for KLM but for Air Canada. Patient Zero, as he became known, had already infected 40 other men. Because stewards travel frequently, the virus spread extremely quickly.

AIDS also affected other businesses and airlines, but Nietsch consciously decided to feature the iconic Dutch airline. The documentary reveals how the disease appeared and spread, based on interviews with colleagues, family members and AMC physicians.

Big family

Nietsch made the documentary without the assistance of KLM, which 30 years after the outbreak of the disease still refuses to discuss the issue. “All the former KLM employees I approached were willing to speak,” says Nietsch. “The people who are still employed by KLM were barred from taking part. At the time, KLM didn’t know how to deal with the disease. It was a huge taboo, and it was commercially uninteresting to discuss these issues with the outside world. The airline could talk about it on an individual basis but not as a company to the general public.”

Nevertheless, KLM did not abandon staff who contracted HIV. Its medical service was in close touch with AMC specialists, employees who fell ill received regular visits from their bosses, and the company chartered buses so colleagues could attend cremations. When stewards who had the disease felt better, they were put back on the roster. According to Nietzsch, “the image that emerges is that KLM was one big family. The airline should be proud of that. Some KLM employees were even buried in blue KLM coffins.”

KLM is not planning to organise a memorial service to mark the 30th anniversary.

Related Article:

AIDS Was a Man-Made Pandemic

Italy, Switzerland, Austria freeze sales of Novartis flu vaccines

Google – AFP, 24 October 2012 

Italy has banned the use of three flu vaccines produced by Novartis

(AFP/File, Lionel Bonaventure)

ROME — Italian, Swiss and Austrian authorities on Wednesday halted the sale of flu vaccines made by Swiss pharmaceutical giant Novartis.

The Italian health ministry said it has banned the sale and use of several flu vaccines produced by Novartis pending tests into possible side-effects.

"The health ministry and the Italian medicines agency (AIFA) have decided to take the precaution of banning immediately the use of the vaccines" Aggripal, Fluad and Influpozzi, it said.

On the basis of information supplied by Novartis, AIFA "has decided that it is necessary to carry out further tests regarding the quality and the safety" of the vaccines, which "can produce collateral effects," the statement said.

In Switzerland, the national drug agency Swissmedic said it was ordering the "immediate halt of flu vaccine deliveries from Novartis," due to "possible impurities".

The alarm was raised after white particles were seen in syringes carrying the vaccines, Swissmedic said, stressing that they could be nothing more than little clumps of the vaccine's components.

The Swiss decision affects some 160,000 vaccine doses, Swissmedic said, adding that it was unclear whether the problem affected vaccines already available in Switzerland.

The freeze on sales of the vaccines and their use was "a simple precaution" and those who had already been vaccinated for the flu "had nothing to worry about", it added.

In Austria, a spokeswoman for Novartis's Austrian subsidiary said that "further deliveries of the Novartis flu vaccines were stopped today (Wednesday)."

She added that the move was a precautionary measure following the moves by Italy and Switzerland.

Related Article:

Germany adds its name to flu vaccine ban - New

Placebo effect may be 'down to genes'

BBC News, 24 October 2012

Related Stories 

• Child placebo pill is criticised
• Placebo sparks brain painkillers

Placebo acupuncture looks real, but
the needles don't go into the body

Why some people respond to treatments that have no active ingredients in them may be down to their genes, a study in the journal PLoS ONE suggests.

The so-called "placebo effect" was examined in 104 patients with irritable bowel syndrome (IBS) in the US.

Those with a particular version of the COMT gene saw an improvement in their health after placebo acupuncture.

The scientists warn that while they hope their findings will be seen in other conditions, more work is needed.

Edzard Ernst, a professor of complementary medicine at the University of Exeter, said: "This is a fascinating but very preliminary result.

"It could solve the age-old question of why some individuals respond to placebo, while others do not.

"And if so, it could impact importantly on clinical practice.

"But we should be cautious - the study was small, we need independent replications, and we need to know whether the phenomenon applies just to IBS or to all diseases."

Gene variants

The placebo effect is when a patient experiences an improvement in their condition while undergoing an inert treatment such as taking a sugar pill or, in this case, placebo acupuncture, where the patient believes they are receiving acupuncture but a sham device prevents the needles going into their body.

Two groups in the study had this type of treatment. One group received it in a business-like clinical manner and the other from a warm supportive practitioner. A third randomly chosen group received no treatment at all.

After three weeks the patients were asked if they had seen an improvement in their IBS, a common gastrointestinal disease that can cause abdominal pain and discomfort.

The team then used blood samples to look at what variant the individual had of the catechol-O-methyltranferase (COMT) gene. This plays a role in the dopamine pathway, a chemical known to produce a feel-good state.

Placebo dosage

Paper author Dr Kathryn Hall, from the Beth Israel Deaconess Medical Center (BIDMC), said this gene had been chosen because "there has been increasing evidence that the neurotransmitter dopamine is activated when people anticipate and respond to placebos".

The researchers found individuals with a COMT variant that triples the amount of dopamine in the front of the brain felt no improvement without treatment but an improvement with the placebo acupuncture.

Ted Kaptchuk, director of the Program in Placebo Studies and Therapeutic Encounter at BIDMC, said: "We wanted to tease apart the different doses of placebo.

"We got an effect in individuals with this specific genetic signature for the general placebo, but an even bigger effect in the elaborate placebo where warmer care was given.

"You can really see the advantage of a positive doctor-patient relationship."

Fabrizio Benedetti, professor of neurophysiology at the University of Turin Medical School, Italy, warned that dopamine may not be the only chemical involved with the placebo effect.

"A previous study on the genetics of placebo in social anxiety disorder showed that it is serotonin that is associated to placebo responsiveness and not dopamine," he said.

"While this is a very interesting work, what we have learned in the past few years is that there is not a single placebo response and a single mechanism, but many, across different medical conditions and therapeutic interventions."

Related Articles:

Study: Placebo or not, acupuncture helps with pain

"The Recalibration of 'Shoulds' " – Jan 26, 2012 (Kryon channelled by Lee Carroll) (Subjects: Religion/Worship, Lightworkers, Food, Health, Prescription Drugs, Homeopathy, Innate (Body intelligence), New Age movement, Global Unity, ... etc.) - (Text version)

“… In this new energy, there is something else that you can try if you are in this category. Do the following with safety, intelligence, common sense and logic. Here is the challenge: The principle of homeopathy is that an almost invisible tincture of a substance is ingested and is seen by your innate. Innate "sees" what you are trying to do and then adjusts the body's chemistry in response. Therefore, you might say that you are sending the body a "signal for balance." The actual tincture is not large enough to affect anything chemically - yet it works!

The body [innate] sees what you're trying to do and then cooperates. In a sense, you might say the body is healing itself because you were able to give it instructions through the homeopathic substance of what to do. So, why not do it with a major drug? Start reducing the dosage and start talking to your cells, and see what happens. If you're not successful, then stop the reduction. However, to your own amazement, you may often be successful over time. ...”

Alma Deutscher, 7-Year-Old Prodigious Composer, May Be This Generation's Mozart

The Huffington Post,  Oct.15, 2012

Seven-year-old Alma Deutscher may not be able to reach the pedals of her piano without a little help from a stack of books, but that does not stop people from identifying the miniature musician as this generation's Mozart.

The youthful pianist, violinist and composer is the latest sensation in the world of prodigious talent. In a video featured by NBC News, the impressive seven-year-old is shown cooly composing a cello sonata and performing her own musical creations on both the piano and violin -- no small feat considering she recently entered grade school.

In fact, the cello sonata is not even the most astonishing accomplishment on the pig-tailed wunderkind's resume. Deutscher, who was first given a violin on her third birthday, wrote a short opera called "The Sweeper of Dreams" earlier this year, reports The Telegraph. The work was submitted to an English National Opera contest for young musicians, though it narrowly missed making it into the final round.

Among those who have been blown away by Deutscher's abilities is comedian and writer Stephen Fry. The English icon stumbled upon her YouTube channel, which has nearly 70,000 views. Fry then tweeted her talents to the world last week, writing: "Simply mind blowing: Alma Deutscher playing her own compositions. A new Mozart?"

Deutscher comes from impressive stock, which might explain her prodigious abilities. The Telegraph writes that both her mother and father are academics. In fact, her father, Guy Deutscher, is a highly regarded linguist and amateur flautist. As a result, the little Deutscher was exposed to the whims of academia at an early age, as her father even included her in one of his linguistic studies when shewas just an infant.

For a taste of Deutscher's genius, here's how the grade schooler describes her creative process: "Normally when I try it's more difficult, but when I'm resting or in bed, I'm kind of relaxed," she says in the video above. 

Related Articles:

More of human DNA is active than was thought

Four-year-old Melbourne artist shows in NY


"The Quantum Factor" – Apr 10, 2011 (Kryon channeled by Lee Carroll) (Subjects: Galaxies, Universe, Intelligent design, Benevolent design, Aliens, Nikola Tesla (Quantum energy), Inter-Planetary Travel, DNA, Genes, Stem Cells, Cells, Rejuvenation, Shift of Human Consciousness, Spontaneous Remission, Religion, Dictators, Africa, China, Nuclear Power, Sustainable Development, Animals, Global Unity.. etc.) - (Text Version)

"..... DNA - A Quantum Force 

Now we get to the core truth, don't we? So I will tell you. The ninety percent of DNA which is quantum, is filled with information, both esoteric and timeless. It is a quantum blueprint for everything you are and have been since you arrived on the planet the first time. DNA contains instruction sets for your life; everything from your full Akashic Record - every single lifetime you have had - to the benevolent creator's fingerprint within the seeds of creation itself. Every single talent you ever had is there, even if you don't have any of those today... the record is there. Every predisposition of weakness and strength are there. Biologically, every single instruction to every single stem cell is there. . ..."

"..... DNA is a Dynamic Molecule, not a static one.

Humanity is stuck in the 3D portion of their biological thinking. In your 3-D life, you simply accept the chemistry you're given. You act as though the three percent gene producing part is all there is. You believe it is a chemical protocol that is unchangeable and simply "you." You don't see it for the way it's designed. It's dynamic and always has been. It's not set, but will continue to simply repeat what it does unless there is another quantum influence on it.

Therefore you live with the 3 percent as though it were all there is, and since it just "came with your body" and seems to control everything, you never talk to it. Many of you come in with pre-dispositions based upon the karma which is put upon you from your past lives. You don't come in clean [without karmic energy]. Instead, you arrive with pre-dispositions, fears and phobias. Some are positive. Perhaps you come in as a prodigy continuing your last life... the 8-year-old who can paint like a master and do brushstrokes that take 30 years to develop. What does that tell you about what must be in the DNA?

Perhaps you come in as the composer, the pianist, the prodigy, the violinist, just waiting until your hands can go on the fingerboard or can reach up and fret the notes. Perhaps you come in knowing how to play the piano, just waiting for your hands to get big enough to do what you used to do... without any lessons. How do you explain that, dear ones? The answer is that all this is contained in the dynamic quantum instruction sets of your DNA... the part you never talk to it. .."

Pharma patent cliff may lead to research drop-off

Deutsche Welle, 23 october 2012

Drug makers are on the brink of a "patent cliff" - many are losing the exclusive rights to produce some of their most popular drugs. Profits will drop off and so too could new research.

It is estimated that pharmaceutical companies will have lost more than $267 billion (205 billion euros) once a raft of patents have expired by 2016.

Some widely used drugs have already been affected.

Last year, Pfizer lost exclusive rights to produce its blockbuster drug, Lipitor - used for reducing blood cholesterol. And this year, Bristol-Myers Squibb and Sanofi's patent on the blood thinning drug Plavix has expired.

The loss in sales from drugs like Lipitor and Plavix are expected to result in cuts to research into new drugs for diseases like Alzheimer's. It is part of a worrying trend in the pharmaceutical industry, according to Christa Müller, who heads the Pharmaceutical Institute at Bonn University.

"Some have spent huge amounts of money on Alzheimer's research in the past ten years and many projects have proven to be unsuccessful," says Müller.

In August, Johnson and Johnson and Pfizer pulled the plug on a joint new treatment for Alzheimer's, which had already cost the two companies more than a billion dollars.

An unprecedented challenge

For a long time, pharmaceutical companies have relied on profits from their most popular drugs to enable them to invest in developing newer drugs.

The work that goes into researching, trialing and marketing a new drug can be as much as $1.5 billion.

Strict regulations are often also blamed for discouraging new research

With further patents on commonly used drugs expiring, or heading towards expiry, their original makers are likely to see their profits drop massively. They will face greater competition from other producers, who could begin to make cheaper, generic versions of their drugs.

Generics can to be cheaper - sometimes up to 90 percent cheaper.

A 30 day supply of Valium costs an estimated $157. But the same supply in generic form - for instance, Diazepam, costs just $1.82.

Some say drug makers are set to lose a lot of money, and this is making them cautious about investing in new research.

"If one company is working on a specific drug target, [another company] won't do it as well because they will be afraid that if they're number two on the market, they will not get back what they invested - drug research has become so expensive," Müller says.

But despite a trend away from research into neurodegenerative diseases - they are seen as too difficult to crack - Bonn University's Pharmaceutical Institute has been able to continue its own research in the field.

They have conducted successful studies into receptors - cell molecules responsible for receiving external signals in the brain. Müller explains her research into receptors could be used in the development of drugs that target specific cells and repair them to stave off the worst of Parkinson's or Alzheimer's.

"It's easier to get funding for a disease like Parkinson's disease or Alzheimer's disease where there is a big need to get new drugs," Müller insists.

Generics increasingly significant

Tropical diseases are also popular research areas.

The Pharmaceutical Institute hopes to get funding for a planned network with African institutes to research tropical diseases like malaria and Schistosomiasis (bilharzia).

India is now home to one of the world's largest generics manufacturers,
Ranbaxy Laboratories

Whereas some western drug makers are cutting back, Africa's pharmaceutical industry is growing, much like in Asia and Latin America.

Tinotenda Sachikonye, an analyst at Frost and Sullivan, says the focus in Africa is shifting from over-the-counter (OTC) medicines like painkillers (aspirin or ibuprofen) to treatments for diseases, like diabetes and cancer.

"The local manufacturers in Nigeria contribute to about 30 percent of all manufacturing revenues in the country, so they've got quite a strong local manufacturing base," Sachikonye says.

Drug production levels are approaching similar levels in other countries like Kenya and Tanzania.

But Sachikonye says there is barely any research into new drugs in Africa as generics represent as much as 70 percent of all the drugs produced.

Generics are also taking on increasing significance in Europe.

A report from the European Federation of Pharmaceutical Industries and Associations suggests spending on generics will rise from $242 billion in 2011 to $430 billion by 2016 in Europe because of the growth in emerging markets and a general transition to generics in developed nations.

Related Article:

Cost of Popular Medicines Set to Plunge as Raft of Patents Expire